Frizzled-2: A potential novel target for molecular pancreatic cancer therapy

被引:4
|
作者
Tomizawa, Minoru [1 ]
Shinozaki, Fuminobu [2 ]
Sugiyama, Takao [3 ]
Yamamoto, Shigenori [4 ]
Sueishi, Makoto [3 ]
Yoshida, Takanobu [5 ]
机构
[1] Natl Hosp Org, Shimoshizu Hosp, Dept Gastroenterol, Chiba 2840003, Japan
[2] Natl Hosp Org, Shimoshizu Hosp, Dept Radiol, Chiba 2840003, Japan
[3] Natl Hosp Org, Shimoshizu Hosp, Dept Rheumatol, Chiba 2840003, Japan
[4] Natl Hosp Org, Shimoshizu Hosp, Dept Pediat, Chiba 2840003, Japan
[5] Natl Hosp Org, Shimoshizu Hosp, Dept Internal Med, Chiba 2840003, Japan
关键词
GROWTH-FACTOR-I; PROLIFERATION; EXPRESSION; MOTILITY; RECEPTOR; PATHWAY; CELLS;
D O I
10.3892/ol.2013.1681
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the present study, pancreatic cancer cell proliferation was analyzed following the suppression of frizzled (Fz)2 expression. Reverse transcription polymerase chain reaction (PCR) was performed using RNA isolated from pancreatic cancer cell lines, PANC-1, NOR-P1, PK-45H, PK-1, PK-59, MIA-Paca2 and KP4. A surgical specimen of pancreatic cancer was immunostained with antibodies specific to Fz2. Cell proliferation assays were performed with MIA-Paca2 cells transfected with small interfering RNA (siRNA) or short hairpin RNA (shRNA) of Fz2. Fz2 was found to be expressed in all pancreatic cancer cell lines, with the exception of NOR-P1. Immunostaining revealed that Fz2 was not expressed in normal pancreatic tissues, while it was expressed in pancreatic cancer cells. The expression levels of cyclin D1 were analyzed by quantitative PCR. The proliferation and expression of cyclin D1 were suppressed with the siRNA and shRNA of Fz2 in the MIA-Paca2 cells. Therefore, Fz2 is a potential target for the molecular therapy of pancreatic cancer.
引用
收藏
页码:74 / 78
页数:5
相关论文
共 50 条
  • [31] Serine hydroxymethyltransferase 2: a novel target for human cancer therapy
    Xie, Min
    Pei, Dong-Sheng
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1671 - 1681
  • [32] ALKBH overexpression in head and neck cancer: potential target for novel anticancer therapy
    Pilzys, Tomas
    Marcinkowski, Michal
    Kukwa, Wojciech
    Garbicz, Damian
    Dylewska, Malgorzata
    Ferenc, Karolina
    Mieczkowski, Adam
    Kukwa, Andrzej
    Migacz, Ewa
    Wolosz, Dominika
    Mielecki, Damian
    Klungland, Arne
    Piwowarski, Jan
    Poznanski, Jaroslaw
    Grzesiuk, Elzbieta
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [33] Novel Targets for Pancreatic Cancer Therapy
    Philip, Philip A.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 19 (02) : 419 - +
  • [34] FoxM1 is a Novel Target of a Natural Agent in Pancreatic Cancer
    Wang, Zhiwei
    Ahmad, Aamir
    Banerjee, Sanjeev
    Azmi, Asfar
    Kong, Dejuan
    Li, Yiwei
    Sarkar, Fazlul H.
    PHARMACEUTICAL RESEARCH, 2010, 27 (06) : 1159 - 1168
  • [35] LAMC1 is a Novel Prognostic Factor and a Potential Therapeutic Target in Gastric Cancer
    Xi, Dayong
    Jia, Qiufang
    Liu, XiaoLong
    Zhang, Lei
    Xu, Bo
    Ma, Zhen
    Ma, YanLing
    Yu, Yang
    Zhang, Fan
    Chen, Hao
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2022, 15 : 3183 - 3198
  • [36] Stathmin is a potential molecular marker and target for the treatment of gastric cancer
    Liu, Xiaolin
    Liu, Hairong
    Liang, Jing
    Yin, Beibei
    Xiao, Junjuan
    Li, Junwei
    Feng, Dongfeng
    Li, Yan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (04): : 6502 - 6509
  • [37] Orexin 2 receptor as a potential target for immunotoxin and antibody-drug conjugate cancer therapy
    Kishida, Masato
    Ishige, Kazunori
    Horibe, Tomohisa
    Tada, Noriko
    Koibuchi, Nobutaka
    Shoda, Junichi
    Kita, Kiyoshi
    Kawakami, Koji
    ONCOLOGY LETTERS, 2012, 3 (03) : 525 - 529
  • [38] FABP5 as a novel molecular target in prostate cancer
    O'Sullivan, Saoirse Elizabeth
    Kaczocha, Martin
    DRUG DISCOVERY TODAY, 2020, 25 (11) : 2056 - 2061
  • [39] Novel Epigenetic Target Therapy for Prostate Cancer: A Preclinical Study
    Naldi, Ilaria
    Taranta, Monia
    Gherardini, Lisa
    Pelosi, Gualtiero
    Viglione, Federica
    Grimaldi, Settimio
    Pani, Luca
    Cinti, Caterina
    PLOS ONE, 2014, 9 (05):
  • [40] HDAC11: A novel target for improved cancer therapy
    Liu, Yan
    Tong, Xuechao
    Hu, Weina
    Chen, Da
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 166